New Sanofi study is yet another win for blockbuster drug

Both primary and secondary endpoints were met in a new phase III trial of Sanofi's bestseller drug Dupixent, this time as a treatment for the rare skin disease prurigo nodularis.

Photo: Thibault Camus/AP/Ritzau Scanpix

Sanofi is working to expand the indications for its blockbuster drug Dupixent. The firm's latest attempt looks to be a success, as a phase III study generated positive results within skin disease prurigo nodularis.

This is the sixth disease for which Dupixent shows a strong effectiveness in phase III tests.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs